Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
16 studies found for:    WAGR
Show Display Options
RSS Create an RSS feed from your search for:
WAGR
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Characterization of WAGR Syndrome and Other Chromosome 11 Gene Deletions
Conditions: WAGR Syndrome;   Wilm's Tumor;   Aniridia;   Urogenital Abnormalities;   Mental Retardation
Intervention:
2 Completed
Has Results
Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic Malignancy
Conditions: Myelodysplastic Syndrome;   Acute Myeloid Leukemia (AML);   Chronic Myeloid Leukemia (CML)
Intervention: Drug: WT1 Peptide Vaccine
3 Completed
Has Results
Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood
Conditions: Leukemia, Acute Myelogenous (AML);   Leukemia, Acute Lymphocytic (ALL);   Leukemia, Chronic Myelogenous (CML);   Myelodysplastic Syndrome (MDS);   Non-Hodgkin's Lymphoma (NHL)
Interventions: Drug: WT1 Peptide-Pulsed Dendritic Cells;   Drug: Donor Lymphocytes;   Drug: IL-4;   Drug: KLH;   Drug: WT1 Peptides;   Drug: Endotoxin;   Drug: Diphenhydramine;   Drug: Acetaminophen
4 Completed
Has Results
Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers
Conditions: Myelodysplastic Syndrome (MDS);   Acute Myeloid Leukemia (AML);   Chronic Myeloid Leukemia (CML)
Interventions: Biological: WT1:126-134;   Biological: PR1:169-177 Peptide;   Drug: GM-CSF (Sargramostim);   Biological: Montanide adjuvant
5 Recruiting Phase II Study of Adjuvant WT-1 Analog Peptide Vaccine in MPM Patients After MSK10-134
Condition: Malignant Pleural Mesothelioma
Interventions: Biological: WT-1-vaccine Montanide + GM-CSF;   Biological: Montanide adjuvant + GM-CSF
6 Completed Safety of Peptide Vaccination for Patients With Myelodysplastic Syndrome
Condition: Myelodysplastic Syndrome (MDS)
Intervention: Drug: WT1 and PR1 Peptide Vaccine
7 Completed WT1 for the Detection of Minimal Residual Disease
Conditions: Leukemia;   Cancer
Intervention: Procedure: WT 1 Testing
8 Active, not recruiting Decitabine Augments for Post Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome
Conditions: Acute Myelocytic Leukemia;   Myelodysplastic Syndromes
Intervention: Drug: decitabine
9 Recruiting WT1 Analog Peptide Vaccine in Patients With Multiple Myeloma Following Autologous Stem Cell Transplantation
Condition: Multiple Myeloma
Interventions: Biological: WT1 Analog Peptide Vaccine;   Biological: Sargramostim (GM-CSF);   Drug: lenalidomide
10 Unknown  Registry for Patients With Wilms' Tumor Suppressor Gene 1 (WT1) Mutation Associated Diseases
Conditions: Denys-Drash Syndrome;   Frasier Syndrome;   Nephrotic Syndrome;   Wilms Tumor
Intervention:
11 Recruiting Randomized Study of Adjuvant WT-1 Analog Peptide Vaccine in Patients With Malignant Pleural Mesothelioma (MPM) After Completion of Combined Modality Therapy
Condition: Malignant Pleural Mesothelioma
Interventions: Biological: WT-1-vaccine Montanide + GM-CSF;   Biological: Montanide adjuvant + GM-CSF
12 Terminated Feasibility Study of Acute Myelogenous Leukemia mRNA Plus Lysate Loaded Dendritic Cell Vaccines
Condition: Leukemia
Intervention: Biological: Autologous Dendritic Cells
13 Completed A Randomized Study of Gemtuzumab Ozogamicin (GO) With Daunorubicine and Cytarabine in Untreated Acute Myeloid Leukemia (AML) Aged of 50-70 Years Old
Condition: Acute Myeloid Leukemia
Interventions: Drug: conventional chemotherapy (AraC + Daunorubicin),;   Drug: Mylotarg associated with conventional chemotherapy (AraC + Daunorubicin),
14 Active, not recruiting Vaccine Therapy in Treating Patients With Myelodysplastic Syndromes
Condition: Myelodysplastic Syndromes
Intervention: Biological: GM-K562 cell vaccine
15 Completed Study of the Pathophysiological Mechanisms Involved in Bleeding Events
Condition: Oculocerebrorenal Syndrome
Intervention: Other: Blood sample
16 Recruiting Clinical Study of DC Plus CIK for Patients With Relapse Acute Leukemia After Allo-HSCT
Condition: Acute Leukemia
Interventions: Biological: Genetically modified DCs combined with CIK cells;   Biological: Donor leukocyte infusions (DLI)

Indicates status has not been verified in more than two years